Unable to get vaccines in the US, the world turns to Russia and China

Although the Biden government topped the list of COVAX donors with a $ 2 billion commitment, the project still lacks $ 800 million of what it needs to achieve its goal of vaccinating 2 billion people in 2021. This reality financial, along with China, Russia and India gaining most of the first vaccine donation headlines, means that it may take months for US stocks to increase in the developing world.

In the meantime, the race to overcome new variants of the virus continues. In the coming weeks, COVAX must deliver vaccines to all participating economies to ensure that those most at risk are protected, wherever they live, ”said Seth Berkley, CEO of Gavi, an alliance that works to vaccinate the world’s children, and a key supporting COVAX.

European countries and the United States are bound to manage a health crisis and a political crisis: namely, the legitimate demand of their citizens to be vaccinated first.

Free from democratic pressure, Beijing can extend more charity and intensify its vaccine diplomacy. Russia, on the other hand, is free to do global business for a different reason: the Kremlin is struggling to convince Russians to use its home vaccine.

But today’s top donors – while reaping the first public relations wins – are unlikely to be able to match COVAX’s growth until 2021.

China and Russia face domestic challenges

For China, the barriers are the effectiveness of its vaccines (only 50% in some tests) and Beijing’s need to eventually vaccinate its own population of 1.4 billion – 97% of whom have not received a vaccine.

Although the Russian Sputnik vaccine is 95 percent effective, it is already experiencing production problems in 15 locations around the world.

The Indian government – echoing the EU – is concerned that it miscalculated with initial generosity and blocked its main manufacturer, the Serum Institute to follow a plan to send 50% of its production abroad, according to the Serum Institute’s CEO, Adar Poonawalla.

Colombia’s vaccine business and schedule illustrates how the balance of global vaccine distribution is likely to shift.

Source